Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.

David M CharytanKenneth W MahaffeyMeg J JardineChristopher P CannonBruce NealHiddo J Lambers HeerspinkRajiv AgarwalGeorge L BakrisDick de ZeeuwAdeera LevinCarol PollockHong ZhangBernard ZinmanNorman RosenthalVlado PerkovicGian Luca Di TannaJie YuKris RogersClare ArnottDavid Collins Wheeler

Published in: BMJ open diabetes research & care (2023)

The glycemic effects of canagliflozin are attenuated at lower eGFR but effects on kidney and cardiac end points are preserved. Non-glycemic effects may be primarily responsible for the kidney and cardioprotective benefits of canagliflozin.22.

Keyphrases

type diabetes
small cell lung cancer
glycemic control
epidermal growth factor receptor
left ventricular
tyrosine kinase
blood glucose
adipose tissue